10-Q: Kymera Reports Increased Losses, Strategic Program Shifts

Kymera Therapeutics reports a significant increase in net losses for Q3 and the first nine months of 2025, alongside strategic program adjustments and a new collaboration.

Summary

• Net loss for the three months ended September 30, 2025, increased to $82.2 million from $62.5 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, increased to $224.4 million from $153.1 million in the same period of 2024.
• Collaboration revenue decreased to $2.8 million for Q3 2025 (from Gilead) compared to $3.7 million for Q3 2024 (from Sanofi).
• Research and development expenses rose to $74.1 million for Q3 2025, up from $60.4 million in Q3 2024, primarily due to increased investment in the STAT6 program.
• General and administrative expenses increased to $17.3 million for Q3 2025 from $15.5 million in Q3 2024.
• An incremental impairment charge of $3.9 million was recorded on long-lived assets in Q3 2025 related to the 2019 Lease facility.
• Cash, cash equivalents, and marketable securities totaled $978.7 million as of September 30, 2025, expected to fund operations into the second half of 2028.
• Completed a follow-on public offering in June/July 2025, raising approximately $288.4 million in gross proceeds.
• Entered into a new strategic collaboration with Gilead Sciences, Inc. for CDK2 degraders, receiving a $40.0 million upfront payment and potential for up to $710.0 million in milestones and tiered royalties.
• Advanced the STAT6 program (KT-621) by completing dosing in the BroADen Phase 1b trial and initiating the BroADen2 Phase 2b clinical trial in Atopic Dermatitis.
• Completed IND-enabling studies for the IRF5 program (KT-579), with an IND submission anticipated in 2025.
• Sanofi decided to stop development of KT-474 (IRAK4) to prioritize the advancement of the next-generation IRAK4 degrader, KT-485/SAR447971, into clinical testing in 2026.
• Made a strategic decision not to advance the TYK2 degrader (KT-295) into clinical development to reallocate resources and extend cash runway.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significantly increased net losses, decreased collaboration revenue, and the discontinuation of a program (KT-295) and a shift in a partnered program (KT-474). While the new Gilead collaboration and extended cash runway are positive, the overall financial performance and pipeline adjustments indicate challenges.

Positives

• Secured a new strategic collaboration with Gilead Sciences, Inc. for CDK2 degraders, including a $40.0 million upfront payment and potential for significant future milestones and royalties.
• Successfully completed a follow-on public offering in June/July 2025, raising approximately $288.4 million in gross proceeds, strengthening the cash position.
• Extended cash runway into the second half of 2028, providing financial stability for ongoing operations and clinical development.
• Advanced the STAT6 program (KT-621) into Phase 2b clinical trials for Atopic Dermatitis, demonstrating progress in a key immunology asset.
• Completed IND-enabling studies for the IRF5 program (KT-579), indicating readiness for potential clinical entry in 2025.
• The company's targeted protein degradation (TPD) platform continues to generate new molecular entities, with a goal to advance at least one new candidate into clinical testing annually.

Negatives

• Reported a significant increase in net loss for the three months ended September 30, 2025, to $82.2 million, up from $62.5 million in the prior year period.
• Accumulated deficit grew to $979.0 million as of September 30, 2025, reflecting continued operating losses since inception.
• Collaboration revenue decreased for both the three-month and nine-month periods compared to the prior year, indicating reduced revenue from existing partnerships.
• Research and development expenses increased substantially, contributing to higher operating losses.
• Incurred an additional $3.9 million impairment charge on long-lived assets related to the former 2019 Lease facility due to worsening market conditions for subleasing.
• Sanofi, a key collaborator, decided to discontinue development of KT-474, shifting focus to a next-generation IRAK4 degrader (KT-485/SAR447971), which introduces a delay for the initial IRAK4 candidate.
• Made a strategic decision to discontinue the TYK2 degrader (KT-295) program, despite completing IND-enabling activities, representing a pipeline reduction.

Risks

• As a clinical-stage company, evaluating business success and future viability is difficult due to limited operating history and no product sales revenue.
• Anticipate continued significant operating losses for the foreseeable future, requiring substantial additional funding.
• Inability to raise capital when needed or on attractive terms could force delays, scaling back, or discontinuation of product candidate development programs or commercialization efforts.
• The targeted protein degradation (TPD) approach is novel and unproven, making it difficult to predict development time, cost, and likelihood of success.
• May not be successful in identifying or discovering additional product candidates, or may expend resources on less profitable or less likely-to-succeed indications.
• Delays or difficulties in initiating or enrolling patients in clinical trials could delay or prevent necessary regulatory approvals.
• Positive results from early preclinical studies and clinical trials are not necessarily predictive of later-stage results, potentially leading to setbacks.
• Pandemics, epidemics, or infectious disease outbreaks could materially and adversely affect business and financial results, disrupting product candidate development.
• Current or future product candidates may cause adverse or undesirable side effects, potentially delaying or preventing regulatory approval, limiting commercial labels, or resulting in negative consequences post-marketing approval.
• Ongoing obligations and continued regulatory review post-approval could result in significant additional expense, and non-compliance could lead to penalties or market withdrawal.
• Reliance on third parties to conduct preclinical studies and clinical trials poses risks if they fail to perform duties, comply with regulations, or meet deadlines.
• Inability to obtain and maintain patent and other intellectual property protection could allow competitors to develop similar technologies and impair commercialization.
• Unstable global economic and geopolitical conditions may have serious adverse consequences on business, financial condition, stock price, and results of operations.
• Increased costs associated with operating as a public company and management diversion to compliance initiatives.
• Adverse developments in the financial services industry could affect access to cash, cash equivalents, and marketable securities.
• Manufacturing product candidates is complex and relies on a limited number of third-party suppliers, with potential for delays or disruptions.
• Intellectual property litigation and infringement claims are expensive, time-consuming, and could divert resources or result in substantial liabilities.
• Dependence on key executives and ability to attract, retain, and motivate qualified personnel is critical for future success.
• Difficulties in managing company development and expansion could disrupt operations.
• Unforeseen global events, natural disasters, or cyberattacks could adversely affect business operations and data security.
• Inability to sublease former office space on favorable terms or subtenant defaults could lead to unexpected costs.
• Changes in tax law, including the One Big Beautiful Bill Act (OBBBA) and Section 174 of the IRC, may adversely affect the company or investors.
• Ability to utilize net operating loss carryforwards and tax credits may be subject to limitations.
• Failure to maintain proper and effective internal control over financial reporting could harm operating results and business operations.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control.
• Designated exclusive forum for certain litigation may limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company anticipates continued significant operating losses and increasing expenses as it advances product candidates through preclinical and clinical trials, prepares IND submissions, scales manufacturing capabilities, expands its pipeline, and seeks regulatory approvals. It expects to finance future operations through existing cash, equity sales, debt financings, or collaborations. The existing cash, cash equivalents, and marketable securities of $978.7 million are projected to fund operations into the second half of 2028, beyond multiple clinical inflection points. The company aims to advance at least one new molecular entity into clinical testing annually and expects to incur significant commercialization expenses if any product candidates receive marketing approval.

Management Comments

• We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated medicines that address significant health problems and that meaningfully improve patients lives.
• Our objective is to develop molecules that are both potent and highly selective, creating the potential for our medicines to uniquely address diseases that are poorly served by current treatment options.
• We believe we have the potential to deliver a compelling value proposition to a significant underserved patient population: small molecule medicines with biologics-like activity through the convenience of oral administration of a pill.
• We intend to leverage our drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines.
• We expect to advance at least one new molecular entity into clinical testing annually.
• We believe the existing cash, cash equivalents and marketable securities of $978.7 million as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028, beyond multiple clinical inflection points in our pipeline.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, specializing in targeted protein degradation (TPD), a novel small molecule therapeutic modality. It aims to address significant unmet medical needs in immunology (STAT6, IRF5, IRAK4 programs) and oncology (CDK2 program). The company positions its oral small molecule medicines as a compelling alternative to injectable biologics for prevalent immune-inflammatory diseases, targeting a large underserved patient population. Competition includes other TPD companies and those using traditional therapeutic modalities, with many competitors possessing greater financial resources and expertise.

Comparison to Industry Standards

• In preclinical studies, KT-621 demonstrated full inhibition of the IL-4/IL-13 pathway with picomolar potency that was superior to dupilumab, and equivalent or superior activity to dupilumab, an established therapy for Atopic Dermatitis.

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that, in management's opinion, are likely to have a material adverse effect on the business.
• Previously initiated a U.S. patent office proceeding (post-grant review) in August 2021 to challenge a third-party patent, which was subsequently disclaimed by the owner.

Related Party Transactions

• Jefferies LLC acted as an underwriter in the June 2025 follow-on public offering, receiving approximately $2.4 million in underwriting commissions. John Maraganore, a member of the Board of Directors, is affiliated with Jefferies.
• Entered into a Registration Rights Agreement concurrently with the June 2025 offering with Baker Brothers Life Sciences, L.P., 667, L.P. (BBA Funds), entities affiliated with Atlas Venture (Atlas), and entities affiliated with BVF Partners L.P. (BVF). These are considered related parties due to affiliations with certain Board members. The agreement provides certain resale registration rights for these entities starting February 28, 2026.
• Entered into an Open Market Sale Agreement with Jefferies LLC on October 31, 2024, for at-the-market offerings of up to $300.0 million of common stock. No shares have been sold under this agreement as of September 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity offerings, as well as the exercise of outstanding warrants and equity awards.
• Employees may benefit from increased headcount and stock-based compensation, but program discontinuations could impact morale or future opportunities.
• Customers and patients may benefit from the advancement of new targeted protein degradation therapies, particularly for inflammatory diseases, but the discontinuation of KT-295 and the shift from KT-474 to KT-485 mean certain initial candidates will not be pursued.
• Collaborators (Gilead, Sanofi) are actively engaged in new or revised agreements, impacting their respective R&D pipelines and potential future revenues.
• Creditors and suppliers may be impacted by the company's continued operating losses and reliance on future funding, though the extended cash runway provides a buffer.

Next Steps

• Advance KT-621 through the BroADen2 Phase 2b clinical trial for Atopic Dermatitis.
• Submit an Investigational New Drug (IND) application for KT-579 (IRF5 program) in 2025.
• Sanofi plans to advance KT-485/SAR447971 (IRAK4 program) into clinical testing in 2026.
• Gilead Sciences, Inc. has an option to license the CDK2 degrader program, which if exercised, would trigger a $45.0 million payment and potential future milestones.
• Continue to evaluate the potential recovery of the 2019 Lease facility through sublease scenarios, with possible future impairment charges.
• Identify and qualify additional manufacturers for API, drug product, and starting materials for current and future product candidates.
• Seek regulatory approval for product candidates that successfully complete clinical development.
• Expand and improve drug discovery platform capabilities and advance research and development activities to grow the product pipeline.
• Potentially build sales, marketing, and distribution capabilities if product candidates receive regulatory approval.

Key Dates

Recommendation

While Kymera Therapeutics reported increased net losses and made strategic decisions to discontinue or shift certain programs (KT-295, KT-474), the company also secured a new collaboration with Gilead and successfully completed a follow-on offering, extending its cash runway into the second half of 2028. This provides a crucial financial buffer for a clinical-stage company. The advancement of the STAT6 program into Phase 2b and the anticipated IND submission for IRF5 are positive pipeline developments. However, the significant cash burn and the inherent risks of early-stage drug development, coupled with the program changes, suggest a 'hold' recommendation. Investors should monitor clinical trial results, further pipeline advancements, and the company's ability to manage its cash flow effectively. The long-term potential of the TPD platform remains, but near-term execution and financial performance present considerable challenges.

Keywords

Kymera Therapeutics, Targeted Protein Degradation, TPD, Biopharmaceutical, Clinical Stage, Immunology, Oncology, STAT6, IRF5, IRAK4, CDK2, Atopic Dermatitis, Drug Development, SEC Filing, 10-Q, Clinical Trials, Preclinical Development, Gilead Collaboration, Sanofi Collaboration, Biotech, Pharmaceutical